focus -WSS

focus

author：focus 2025-09-06 04:30:03 - browse：2477

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What to watch for from Zogenix and Amicus clinical trials

hotspot

WSS

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

The battle over 'scope creep' and who gets to be called 'doctor'

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

'Weather

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

What does generative AI mean for health care? We asked experts

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

https://cbu01.alicdn.com/img/ibank/2017/225/473/4293374522_1748622931.220x220xz.jpg

Truvian presents data for its desktop blood

DIEP, the 'gold standard' of breast reconstruction, is under threat

What AstraZeneca

Supreme Court strikes down use of affirmative action

Russian and Belarusian players banned from a women's tennis tournament in Prague

Apple is now the first public company to be valued at $3 trillion

Biogen says it will cut costs by $700 million, slash 1,000 jobs

hotspot

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Snowpack in the West is melting rapidly. Where will all that extra water go?

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

'Weather

What causes rare myocarditis in young men after Covid vaccines?

Truvian presents data for its desktop blood

hotspot

hotspot

knowledge

knowledge